These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30196298)

  • 1. Connexin 43: a New Therapeutic Target Against Chronic Kidney Disease.
    Prakoura N; Kavvadas P; Chadjichristos CE
    Cell Physiol Biochem; 2018; 49(3):985. PubMed ID: 30196298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Targets for Therapy of Renal Fibrosis.
    Prakoura N; Hadchouel J; Chatziantoniou C
    J Histochem Cytochem; 2019 Sep; 67(9):701-715. PubMed ID: 31116064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin in kidney diseases.
    Prakoura N; Chatziantoniou C
    Cell Mol Life Sci; 2017 Dec; 74(23):4315-4320. PubMed ID: 28884334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Connexin 43 in Renal Disease: Insights from In Vivo Models of Experimental Nephropathy.
    Roger E; Boutin L; Chadjichristos CE
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting connexin 43 protects against the progression of experimental chronic kidney disease in mice.
    Abed A; Toubas J; Kavvadas P; Authier F; Cathelin D; Alfieri C; Boffa JJ; Dussaule JC; Chatziantoniou C; Chadjichristos CE
    Kidney Int; 2014 Oct; 86(4):768-79. PubMed ID: 24850151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease: Targeting connexin-43 reduces progression of CKD in mice.
    Sidaway P
    Nat Rev Nephrol; 2014 Aug; 10(8):424. PubMed ID: 24914584
    [No Abstract]   [Full Text] [Related]  

  • 7. Decreased Expression of Connexin 43 Blunts the Progression of Experimental GN.
    Kavvadas P; Abed A; Poulain C; Authier F; Labéjof LP; Calmont A; Afieri C; Prakoura N; Dussaule JC; Chatziantoniou C; Chadjichristos CE
    J Am Soc Nephrol; 2017 Oct; 28(10):2915-2930. PubMed ID: 28667079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytoskeleton as a novel target for treatment of renal fibrosis.
    Parrish AR
    Pharmacol Ther; 2016 Oct; 166():1-8. PubMed ID: 27343756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Connexin43 regulates high glucose-induced expression of fibronectin, ICAM-1 and TGF-β1 via Nrf2/ARE pathway in glomerular mesangial cells.
    Chen Z; Xie X; Huang J; Gong W; Zhu X; Chen Q; Huang J; Huang H
    Free Radic Biol Med; 2017 Jan; 102():77-86. PubMed ID: 27840317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
    Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
    Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Krüppel-like Factor 15: A Potential Therapeutic Target For Kidney Disease.
    Wang L; Lin W; Chen J
    Int J Biol Sci; 2019; 15(9):1955-1961. PubMed ID: 31523196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics of kidney disease.
    Wanner N; Bechtel-Walz W
    Cell Tissue Res; 2017 Jul; 369(1):75-92. PubMed ID: 28286899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMP-7 Signaling and its Critical Roles in Kidney Development, the Responses to Renal Injury, and Chronic Kidney Disease.
    Manson SR; Austin PF; Guo Q; Moore KH
    Vitam Horm; 2015; 99():91-144. PubMed ID: 26279374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of connexin-based therapeutic approaches to target inflammatory diseases.
    O'Carroll SJ; Becker DL; Davidson JO; Gunn AJ; Nicholson LF; Green CR
    Methods Mol Biol; 2013; 1037():519-46. PubMed ID: 24029957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the role and mechanism of Wnt/β-catenin signalling in kidney fibrosis.
    Zuo Y; Liu Y
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():38-43. PubMed ID: 30298654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysyl oxidase‑like 2 is expressed in kidney tissue and is associated with the progression of tubulointerstitial fibrosis.
    Choi SE; Jeon N; Choi HY; Shin JI; Jeong HJ; Lim BJ
    Mol Med Rep; 2017 Sep; 16(3):2477-2482. PubMed ID: 28677767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of Akt signaling in chronic kidney disease.
    Lan A; Du J
    Nephrol Dial Transplant; 2015 Mar; 30(3):385-94. PubMed ID: 24891436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connexin43 gap junction protein plays an essential role in morphogenesis of the embryonic chick face.
    McGonnell IM; Green CR; Tickle C; Becker DL
    Dev Dyn; 2001 Nov; 222(3):420-38. PubMed ID: 11747077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astaxanthin ameliorates experimental diabetes-induced renal oxidative stress and fibronectin by upregulating connexin43 in glomerular mesangial cells and diabetic mice.
    Chen Q; Tao J; Li G; Zheng D; Tan Y; Li R; Tian L; Li Z; Cheng H; Xie X
    Eur J Pharmacol; 2018 Dec; 840():33-43. PubMed ID: 30268666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connexin43 plays diverse roles in co-ordinating cell migration and wound closure events.
    Lorraine C; Wright CS; Martin PE
    Biochem Soc Trans; 2015 Jun; 43(3):482-8. PubMed ID: 26009195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.